Australia will be paying nearly $1 billion to a privatised company providing pharmaceutical products that were developed when we owned it, writes Professor John Quiggin.
Paying for what we used to own: The strange case of CSL
Australia will be paying nearly $1 billion to a privatised company providing pharmaceutical products that were developed when we owned it, writes Professor John Quiggin.
Paying for what we used to own: The strange case of CSL
